From FMRP Function to Potential Therapies for Fragile X Syndrome
Open accessThe DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Abstract
Fragile X syndrome (FXS) is caused by mutations in the fragile X mental retardation 1 (FMR1) gene. Most FXS cases occur due to the expansion of the CGG trinucleotide repeats in the 5′ un-translated region of FMR1, which leads to hypermethylation and in turn silences the expression of FMRP (fragile X mental retardation protein). Numerous studies have demonstrated that FMRP interacts with both coding and non-coding RNAs and represses protein synthesis at dendritic and synaptic locations. In the absence of FMRP, the basal protein translation is enhanced and not responsive to neuronal stimulation. The altered protein translation may contribute to functional abnormalities in certain aspects of synaptic plasticity and intracellular signaling triggered by Gq-coupled receptors. This review focuses on the current understanding of FMRP function and potential therapeutic strategies that are mainly based on the manipulation of FMRP targets and knowledge gained from FXS pathophysiology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FMRP Stalls Ribosomal Translocation on mRNAs Linked to Synaptic Function and Autism
Darnell, J. C., Van Driesche, S. J., Zhang, C., Hung, K. Y. S., Mele, A., Fraser, C. E., Stone, E. F., Chen, C., Fak, J. J., Chi, S. W., et al. (2011) · Cell · doi:10.1016/j.cell.2011.06.013 · Cited by 2,072 · cited 10×
“Most of the FMRP binding sites are in the coding region but not in the 50 or 30 UTR of the mRNA targets and no specific sequence or structural feature has been identified as preferred FMRP-binding motifs [82].”
BackgroundInfluentialThe mGluR theory of fragile X mental retardation
Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580 · cited 2×
“Consequently, certain aspects of mGluR1/5- and NMDAR-dependent synaptic plasticity (such as long-term depression and long-term potentiation) are altered in Fmr1 KO mice [95, 96].”
BackgroundAbsence of expression of the FMR-1 gene in fragile X syndrome
Pieretti, M., Zhang, F., Fu, Y.-H., Warren, S. T., Oostra, B. A., Caskey, C. T., & Nelson, D. L. (1991) · Cell · doi:10.1016/0092-8674(91)90125-i · Cited by 1,476
Altered synaptic plasticity in a mouse model of fragile X mental retardation
Huber, K. M., Gallagher, S. M., Warren, S. T., & Bear, M. F. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122205699 · Cited by 1,349 · cited 1×
“[97] showed that synaptic long-term depression (LTD) triggered by mGluR1/5 agonist DHPG is enhanced at the CA1 synapses in Fmr1 KO mice.”
BackgroundBrown, V., Jin, P., Ceman, S., Darnell, J. C., O'Donnell, W. T., Tenenbaum, S. A., Jin, X., Feng, Y., Wilkinson, K. D., Keene, J. D., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00568-2 · Cited by 1,109
Correction of Fragile X Syndrome in Mice
Dölen, G., Osterweil, E., Rao, B. S. S., Smith, G. B., Auerbach, B. D., Chattarji, S., & Bear, M. F. (2007) · Neuron · doi:10.1016/j.neuron.2007.12.001 · Cited by 979
Regulation of Synaptic Structure and Function by FMRP-Associated MicroRNAs miR-125b and miR-132
Edbauer, D., Neilson, J. R., Foster, K. A., Wang, C.-F., Seeburg, D. P., Batterton, M. N., Tada, T., Dolan, B. M., Sharp, P. A., & Sheng, M. (2010) · Neuron · doi:10.1016/j.neuron.2010.01.005 · Cited by 735 · cited 9×
“results in longer and thinner spine [84], which is a cellular phenotype of FXS [58].”
InfluentialFMRP targets distinct mRNA sequence elements to regulate protein expression
Ascano, M., Mukherjee, N., Bandaru, P., Miller, J. B., Nusbaum, J. D., Corcoran, D. L., Langlois, C., Munschauer, M., Dewell, S., Hafner, M., et al. (2012) · Nature · doi:10.1038/nature11737 · Cited by 701 · cited 10×
“Pik3cb PI3 K P110b catalytic subunit HT [83] :Protein :Activity [90, 133] :Translation :Activation [90] Protein synthesis, spine abnormality, AMPA receptor internalization [90] LY294002 wortmannin”
BackgroundMethodInfluentialMarble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety
Thomas, A., Burant, A., Bui, N., Graham, D., Yuva-Paylor, L. A., & Paylor, R. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1466-y · Cited by 698
DNA methylation represses FMR-1 transcription in fragile X syndrome
Sutcliffe, J. S., Nelson, D. L., Zhang, F., Pieretti, M., Caskey, C. T., Saxe, D., & Warren, S. T. (1992) · Human Molecular Genetics · doi:10.1093/hmg/1.6.397 · Cited by 680
Zalfa, F., Giorgi, M., Primerano, B., Moro, A., Di Penta, A., Reis, S., Oostra, B., & Bagni, C. (2003) · Cell · doi:10.1016/s0092-8674(03)00079-5 · Cited by 676 · cited 3×
“CoIP [168] :Protein [168] ;Protein [159] :Translation [100, 125] mGluR-LTD [125]”
Weiler, I. J., Irwin, S. A., Klintsova, A. Y., Spencer, C. M., Brazelton, A. D., Miyashiro, K., Comery, T. A., Patel, B., Eberwine, J., & Greenough, W. T. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.10.5395 · Cited by 644 · cited 3×
“The activation of mGluR1/5 triggers rapid increase in FMRP translation [68] but it is followed by FMRP degradation and de-phosphorylation, which may cause Table 2 continued”
BackgroundThe protein product of the fragile X gene, FMR1, has characteristics of an RNA-binding protein.
Siomi, H., Siomi, M. C., Nussbaum, R. L., & Dreyfuss, G. (1993) · Cell · doi:10.1016/0092-8674(93)90420-u · Cited by 641
Jacquemont, S., Curie, A., des Portes, V., Torrioli, M. G., Berry-Kravis, E., Hagerman, R. J., Ramos, F. J., Cornish, K., He, Y., Paulding, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001708 · Cited by 609 · cited 3×
“Importantly, differences in genetic background and environmental factors possibly contribute to the fact that FXS patients do not respond equally to behavioral and medical treatment [66, 67].”
BackgroundThe Fragile X Syndrome Protein Represses Activity-Dependent Translation through CYFIP1, a New 4E-BP
Napoli, I., Mercaldo, V., Boyl, P. P., Eleuteri, B., Zalfa, F., De Rubeis, S., Di Marino, D., Mohr, E., Massimi, M., Falconi, M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.07.031 · Cited by 609
Dysregulation of mTOR signaling in fragile X syndrome
Sharma, A., Hoeffer, C. A., Takayasu, Y., Miyawaki, T., McBride, S. M., Klann, E., & Zukin, R. S. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3696-09.2010 · Cited by 557
Feng, Y., Gutekunst, C.-A., Eberhart, D. E., Yi, H., Warren, S. T., & Hersch, S. M. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-05-01539.1997 · Cited by 532
Molecular Mechanisms of Fragile X Syndrome: A Twenty-Year Perspective
Santoro, M. R., Bray, S. M., & Warren, S. T. (2012) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132457 · Cited by 528 · cited 2×
“It is estimated that FMRP binds to roughly 4 % of the mRNAs in the brain [1].”
BackgroundHou, L., & Klann, E. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.0995-04.2004 · Cited by 527
Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP
Yan, Q. J., Rammal, M., Tranfaglia, M., & Bauchwitz, R. P. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.06.004 · Cited by 521
Park, S., Park, J. M., Kim, S., Kim, J.-A., Shepherd, J. D., Smith-Hicks, C. L., Chowdhury, S., Kaufmann, W., Kuhl, D., Ryazanov, A. G., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.05.023 · Cited by 516 · cited 4×
“Genetic deletion of Arc in wild type and Fmr1 KO mice results in no significant mGluR1/5-LTD [125].”
BackgroundInfluentialDictenberg, J. B., Swanger, S. A., Antar, L. N., Singer, R. H., & Bassell, G. J. (2008) · Developmental Cell · doi:10.1016/j.devcel.2008.04.003 · Cited by 511
RNA cargoes associating with FMRP reveal deficits in cellular functioning in Fmr1 null mice
Miyashiro, K. Y., Beckel-Mitchener, A., Purk, T. P., Becker, K. G., Barret, T., Liu, L., Carbonetto, S., Weiler, I. J., Greenough, W. T., & Eberwine, J. (2003) · Neuron · doi:10.1016/s0896-6273(03)00034-5 · Cited by 495
The translation of translational control by FMRP: therapeutic targets for FXS
Darnell, J. C., & Klann, E. (2013) · Nature Neuroscience · doi:10.1038/nn.3379 · Cited by 491 · cited 1×
“Possible mechanisms include minocyclinemediated inhibition of ribosome function [165] or MMP9 (matrix metallopeptidase 9), which is an FMRP target whose expression level is elevated in FXS [41, 166].”
BackgroundChronic Pharmacological mGlu5 Inhibition Corrects Fragile X in Adult Mice
Michalon, A., Sidorov, M., Ballard, T. M., Ozmen, L., Spooren, W., Wettstein, J. G., Jaeschke, G., Bear, M. F., & Lindemann, L. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.009 · Cited by 489
Waung, M. W., Pfeiffer, B. E., Nosyreva, E. D., Ronesi, J. A., & Huber, K. M. (2008) · Neuron · doi:10.1016/j.neuron.2008.05.014 · Cited by 474
The fragile X mental retardation protein binds specifically to its mRNA via a purine quartet motif
Schaeffer, C., Bardoni, B., Mandel, J., Ehresmann, B., Ehresmann, C., & Moine, H. (2001) · The EMBO Journal · doi:10.1093/emboj/20.17.4803 · Cited by 471 · cited 1×
“Fmr1 FMRP In vitro [174] ;Or lack of expression :Translation followed by degradation [68, 92, 98, 99]”
BackgroundHou, L., Antion, M. D., Hu, D., Spencer, C. M., Paylor, R., & Klann, E. (2006) · Neuron · doi:10.1016/j.neuron.2006.07.005 · Cited by 469 · cited 5×
“Fmr1 FMRP In vitro [174] ;Or lack of expression :Translation followed by degradation [68, 92, 98, 99]”
BackgroundInfluentialBilousova, T. V., Dansie, L., Ngo, M., Aye, J., Charles, J. R., Ethell, D. W., & Ethell, I. M. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.061796 · Cited by 465 · cited 4×
“Interestingly, independent groups have found that Fmr1 KO mice show more [41], normal [42], or less anxiety [43] in the elevated plus maze”
BackgroundInfluentialMuddashetty, R. S., Kelić, S., Gross, C., Xu, M., & Bassell, G. J. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.0937-07.2007 · Cited by 421
A pilot open label, single dose trial of fenobam in adults with fragile X syndrome
Berry-Kravis, E., Hessl, D., Coffey, S., Hervey, C., Schneider, A., Yuhas, J., Hutchison, J., Snape, M., Tranfaglia, M., Nguyen, D. V., et al. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.063701 · Cited by 411
Eberhart, D. (1996) · Human Molecular Genetics · doi:10.1093/hmg/5.8.1083 · Cited by 390
Osterweil, E. K., Krueger, D. D., Reinhold, K., & Bear, M. F. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3888-10.2010 · Cited by 384 · cited 8×
“Pharmacological inhibition of ERK1/2 reduces AGS, elevated protein translation, and prolonged epileptiform discharges in Fmr1 KO mice [38, 89].”
BackgroundInfluentialDeng, P.-Y., Rotman, Z., Blundon, J. A., Cho, Y., Cui, J., Cavalli, V., Zakharenko, S. S., & Klyachko, V. A. (2013) · Neuron · doi:10.1016/j.neuron.2012.12.018 · Cited by 354
Altered anxiety‐related and social behaviors in the Fmr1 knockout mouse model of fragile X syndrome
Spencer, C. M., Alekseyenko, O., Serysheva, E., Yuva‐Paylor, L. A., & Paylor, R. (2005) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2005.00123.x · Cited by 349 · cited 2×
“Fmr1 KO mice show less social dominance than wild type animals in the social dominance tube test [40, 50].”
BackgroundBerry-Kravis, E. M., Hessl, D., Rathmell, B., Zarevics, P., Cherubini, M., Walton-Bowen, K., Mu, Y., Nguyen, D. V., Gonzalez-Heydrich, J., Wang, P. P., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004214 · Cited by 328 · cited 1×
“A Phase 2 randomized, double blind, and placebo controlled crossover trial with STX209 in 55 males and 8 females showed that STX209 treatment improves social behavior in all patients [157].”
BackgroundFragile X syndrome: causes, diagnosis, mechanisms, and therapeutics
Bagni, C., Tassone, F., Neri, G., & Hagerman, R. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63141 · Cited by 321 · cited 2×
“The incidence of FXS in males is approximately 1 in 2,500–5,000 and in females is 1 in 4,000–6,000 [2].”
BackgroundDecreased expression of the GABAA receptor in fragile X syndrome
D'Hulst, C., De Geest, N., Reeve, S. P., Van Dam, D., De Deyn, P. P., Hassan, B. A., & Kooy, R. F. (2006) · Brain Research · doi:10.1016/j.brainres.2006.08.115 · Cited by 318
Tsai, N.-P., Wilkerson, J. R., Guo, W., Maksimova, M. A., DeMartino, G. N., Cowan, C. W., & Huber, K. M. (2012) · Cell · doi:10.1016/j.cell.2012.11.040 · Cited by 316 · cited 1×
“Dlg4 PSD-95 HT [82], miR125a [85], Gquadruplex [91] :Protein [91] ;Protein degradation [171]”
Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice
de Vrij, F. M. S., Levenga, J., van der Linde, H. C., Koekkoek, S. K., De Zeeuw, C. I., Nelson, D. L., Oostra, B. A., & Willemsen, R. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.04.002 · Cited by 313 · cited 14×
“Specifically, administration of mGluR5 antagonist MPEP attenuates the elevated protein translation [89, 90], the enhanced AMPAR internalization [101], the abnormal spine morphology and PPI ([49] but also see [54]), AGS, hyperactivity [39], and repetitive behavior [54] in Fmr1 KO mice.”
BackgroundResultInfluentialParadee, W., Melikian, H. E., Rasmussen, D. L., Kenneson, A., Conn, P. J., & Warren, S. T. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00285-7 · Cited by 305 · cited 3×
“This complements an earlier study documenting that LTP induced by a stronger TBS (10 burst) is normal in the Fmr1 mutant hippocampus [28].”
BackgroundResultLeigh, M. J. S., Nguyen, D. V., Mu, Y., Winarni, T. I., Schneider, A., Chechi, T., Polussa, J., Doucet, P., Tassone, F., Rivera, S. M., et al. (2013) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0b013e318287cd17 · Cited by 298 · cited 1×
“A double blind, placebo-controlled, crossover trial with minocycline treatment in FXS children resulted in improvements in anxiety and mood-related behavior [163].”
BackgroundFMRP Mediates mGluR5-Dependent Translation of Amyloid Precursor Protein
Westmark, C. J., & Malter, J. S. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050052 · Cited by 296 · cited 4×
“App APP HT [82, 83], CoIP [127] :Protein [126] :Translation [127] AGS, hyperactivity, spines, mGluR-LTD [126]”
BackgroundInfluentialAudiogenic Seizures Susceptibility in Transgenic Mice with Fragile X Syndrome
Musumeci, S. A., Bosco, P., Calabrese, G., Bakker, C., De Sarro, G. B., Elia, M., Ferri, R., & Oostra, B. A. (2000) · Epilepsia · doi:10.1111/j.1528-1157.2000.tb01499.x · Cited by 289
Darnell, J. C., Fraser, C. E., Mostovetsky, O., Stefani, G., Jones, T. A., Eddy, S. R., & Darnell, R. B. (2005) · Genes & Development · doi:10.1101/gad.1276805 · Cited by 287
Inhibition of p21-activated kinase rescues symptoms of fragile X syndrome in mice
Hayashi, M. L., Rao, B. S. S., Seo, J.-S., Choi, H.-S., Dolan, B. M., Choi, S.-Y., Chattarji, S., & Tonegawa, S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705003104 · Cited by 281 · cited 19×
“Specifically, administration of mGluR5 antagonist MPEP attenuates the elevated protein translation [89, 90], the enhanced AMPAR internalization [101], the abnormal spine morphology and PPI ([49] but also see [54]), AGS, hyperactivity [39], and repetitive behavior [54] in Fmr1 KO mice.”
BackgroundInfluentialTodd, P. K., Mack, K. J., & Malter, J. S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2336265100 · Cited by 280
Sensorimotor gating abnormalities in young males with fragile X syndrome and Fmr1-knockout mice.
Frankland, P. W., Wang, Y., Rosner, B., Shimizu, T., Balleine, B. W., Dykens, E. M., Ornitz, E. M., & Silva, A. J. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001432 · Cited by 275 · cited 1×
“Reduced PPI (a symptom observed in human FXS patients) [47] is seen in some investigations using Fmr1 KO mice [48, 49], while other reports have described increased PPI [35, 42, 45–47].”
ResultRescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486
Dolan, B. M., Duron, S. G., Campbell, D. A., Vollrath, B., Rao, B. S. S., Ko, H.-Y., Lin, G. G., Govindarajan, A., Choi, S.-Y., & Tonegawa, S. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219383110 · Cited by 260 · cited 17×
“Specifically, administration of mGluR5 antagonist MPEP attenuates the elevated protein translation [89, 90], the enhanced AMPAR internalization [101], the abnormal spine morphology and PPI ([49] but also see [54]), AGS, hyperactivity [39], and repetitive behavior [54] in Fmr1 KO mice.”
BackgroundInfluentialDisrupted Homer scaffolds mediate abnormal mGluR5 function in a mouse model of fragile X syndrome
Ronesi, J. A., Collins, K. A., Hays, S. A., Tsai, N.-P., Guo, W., Birnbaum, S. G., Hu, J.-H., Worley, P. F., Gibson, J. R., & Huber, K. M. (2012) · Nature Neuroscience · doi:10.1038/nn.3033 · Cited by 251 · cited 4×
“Homer 1 Homer1 HT [83] Unchanged [137] Restored mGluR5 signaling, AGS, anxiety phenotype in open field [137] 1020 Neurochem Res (2014) 39:1016–1031”
BackgroundInfluentialHenderson, C., Wijetunge, L., Kinoshita, M. N., Shumway, M., Hammond, R. S., Postma, F. R., Brynczka, C., Rush, R., Thomas, A., Paylor, R., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004218 · Cited by 249 · cited 18×
“Specifically, administration of mGluR5 antagonist MPEP attenuates the elevated protein translation [89, 90], the enhanced AMPAR internalization [101], the abnormal spine morphology and PPI ([49] but also see [54]), AGS, hyperactivity [39], and repetitive behavior [54] in Fmr1 KO mice.”
BackgroundInfluentialNakamoto, M., Nalavadi, V., Epstein, M. P., Narayanan, U., Bassell, G. J., & Warren, S. T. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707484104 · Cited by 245 · cited 3×
“Specifically, administration of mGluR5 antagonist MPEP attenuates the elevated protein translation [89, 90], the enhanced AMPAR internalization [101], the abnormal spine morphology and PPI ([49] but also see [54]), AGS, hyperactivity [39], and repetitive behavior [54] in Fmr1 KO mice.”
BackgroundOsterweil, E. K., Chuang, S.-C., Chubykin, A. A., Sidorov, M., Bianchi, R., Wong, R. K. S., & Bear, M. F. (2013) · Neuron · doi:10.1016/j.neuron.2012.01.034 · Cited by 230 · cited 18×
“Although, as a major downstream effector of mGluR1/5 signaling, ERK1/2 shows higher activity in Fmr1 KO neurons, its total expression level is not changed [139].”
BackgroundInfluentialOpen-label add-on treatment trial of minocycline in fragile X syndrome.
Paribello, C., Tao, L., Folino, A., Berry-Kravis, E., Tranfaglia, M., Ethell, I. M., & Ethell, D. W. (2010) · BMC Neurology · doi:10.1186/1471-2377-10-91 · Cited by 223 · cited 1×
“In another open label study, 20 FXS individuals treated with minocycline showed improvement in irritability and other global behavior tests [162].”
BackgroundChiurazzi, P., Grazia Pomponi, M., Pietrobono, R., Bakker, C. E., Neri, G., & Oostra, B. A. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.12.2317 · Cited by 217
Open-Label Treatment Trial of Lithium to Target the Underlying Defect in Fragile X Syndrome
Berry-Kravis, E., Sumis, A., Hervey, C., Nelson, M., Porges, S. W., Weng, N., Weiler, I. J., & Greenough, W. T. (2008) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0b013e31817dc447 · Cited by 215 · cited 2×
“However, 7 individuals had side effects of polydipsia and polyuria [66].”
BackgroundWeiler, I. J., Spangler, C. C., Klintsova, A. Y., Grossman, A. W., Kim, S. H., Bertaina-Anglade, V., Khaliq, H., de Vries, F. E., Lambers, F. A. E., Hatia, F., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407533101 · Cited by 210 · cited 1×
“As opposed to wild type neurons, Fmr1 KO neurons do not show increased translation following the activation of mGluR1/5 [85, 91, 92], NMDAR [93], and upon membrane depolarization [94].”
BackgroundA novel function for fragile X mental retardation protein in translational activation
Bechara, E. G., Didiot, M. C., Melko, M., Davidovic, L., Bensaid, M., Martin, P., Castets, M., Pognonec, P., Khandjian, E. W., Moine, H., et al. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000016 · Cited by 206 · cited 3×
“Shank3 SHANK3 HT [82] :Protein [158] Sod1 SOD1 In vitro [76] ;Protein [76]”
BackgroundIn Vitro Reactivation of the FMR1 Gene Involved in Fragile X Syndrome
Chiurazzi, P., Pomponi, M. G., Willemsen, R., Oostra, B. A., & Neri, G. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.1.109 · Cited by 198
Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome
Hoeffer, C. A., Sanchez, E., Hagerman, R. J., Mu, Y., Nguyen, D. V., Wong, H., Whelan, A. M., Zukin, R. S., Klann, E., & Tassone, F. (2012) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2012.00768.x · Cited by 198
FMRP Acts as a Key Messenger for Dopamine Modulation in the Forebrain
Wang, H., Wu, L.-J., Kim, S. S., Lee, F. J. S., Gong, B., Toyoda, H., Ren, M., Shang, Y.-Z., Xu, H., Liu, F., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.027 · Cited by 186
Self-citationFmr1 knockout mouse has a distinctive strain-specific learning impairment
Dobkin, C., Rabe, A., Dumas, R., El Idrissi, A., Haubenstock, H., & Ted Brown, W. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00292-x · Cited by 179
Genetic-background modulation of core and variable autistic-like symptoms in Fmr1 knock-out mice
Pietropaolo, S., Guilleminot, A., Martin, B., D'Amato, F. R., & Crusio, W. E. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017073 · Cited by 178 · cited 5×
“Fmr1 mutants are less interested in social novelty and social interaction [33, 43, 46, 51].”
BackgroundInfluentialGross, C., Yao, X., Pong, D. L., Jeromin, A., & Bassell, G. J. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.6661-10.2011 · Cited by 161 · cited 3×
“[148] found that FMRP facilitates the translation of Kv4.”
BackgroundHigh MMP-9 activity levels in fragile X syndrome are lowered by minocycline
Dziembowska, M., Pretto, D. I., Janusz, A., Kaczmarek, L., Leigh, M. J., Gabriel, N., Durbin‐Johnson, B., Hagerman, R. J., & Tassone, F. (2013) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36023 · Cited by 161 · cited 2×
“Possible mechanisms include minocyclinemediated inhibition of ribosome function [165] or MMP9 (matrix metallopeptidase 9), which is an FMRP target whose expression level is elevated in FXS [41, 166].”
BackgroundNiere, F., Wilkerson, J. R., & Huber, K. M. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.4650-11.2012 · Cited by 153 · cited 2×
“Its involvement in FXS is implicated by the observation that the basal level of Arc expression is elevated in Fmr1 KO neurons [98].”
BackgroundMin, W. W., Yuskaitis, C. J., Yan, Q., Sikorski, C., Chen, S., Jope, R. S., & Bauchwitz, R. P. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.09.017 · Cited by 146
Giuffrida, R., Musumeci, S., D'Antoni, S., Bonaccorso, C. M., Giuffrida-Stella, A. M., Oostra, B. A., & Catania, M. V. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.0932-05.2005 · Cited by 141 · cited 6×
“However, another study has shown that the expression level of mGluR5 is not changed in the forebrain and cerebellum of Fmr1 KO mice [136].”
BackgroundInfluentialA mouse model of the human Fragile X syndrome I304N mutation
Zang, J. B., Nosyreva, E. D., Spencer, C. M., Volk, L. J., Musunuru, K., Zhong, R., Stone, E. F., Yuva-Paylor, L. A., Huber, K. M., Paylor, R., et al. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000758 · Cited by 138
Strumbos, J. G., Brown, M. R., Kronengold, J., Polley, D. B., & Kaczmarek, L. K. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1125-10.2010 · Cited by 135 · cited 1×
“2) [75, 93, 147, 148], ligand-gated channels (such as GABA-A, AMPA, and NMDA receptors) [82, 84, 149], and G protein-coupled GABA-B receptors [82].”
Pacey, L. K. K., Heximer, S. P., & Hampson, D. R. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.056127 · Cited by 133 · cited 17×
“Specifically, administration of mGluR5 antagonist MPEP attenuates the elevated protein translation [89, 90], the enhanced AMPAR internalization [101], the abnormal spine morphology and PPI ([49] but also see [54]), AGS, hyperactivity [39], and repetitive behavior [54] in Fmr1 KO mice.”
BackgroundInfluentialMolecular dissection of the events leading to inactivation of the FMR1 gene
Pietrobono, R., Tabolacci, E., Zalfa, F., Zito, I., Terracciano, A., Moscato, U., Bagni, C., Oostra, B., Chiurazzi, P., & Neri, G. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi024 · Cited by 130
Nalavadi, V. C., Muddashetty, R. S., Gross, C., & Bassell, G. J. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5057-11.2012 · Cited by 128
Plante, I., Davidovic, L., Ouellet, D. L., Gobeil, L.-A., Tremblay, S., Khandjian, E. W., & Provost, P. (2006) · BioMed Research International · doi:10.1155/jbb/2006/64347 · Cited by 119 · cited 3×
“The interaction between FMRP and components of the RISC (such as AGO1/2 and Dicer) may provide another layer of control on RNA metabolism.”
BackgroundReversal of Fragile X Phenotypes by Manipulation of AβPP/Aβ Levels in Fmr1KO Mice
Westmark, C. J., Westmark, P. R., O'Riordan, K. J., Ray, B. C., Hervey, C. M., Salamat, M. S., Abozeid, S. H., Stein, K. M., Stodola, L. A., Tranfaglia, M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026549 · Cited by 110 · cited 3×
“App APP HT [82, 83], CoIP [127] :Protein [126] :Translation [127] AGS, hyperactivity, spines, mGluR-LTD [126]”
BackgroundUtari, A., Chonchaiya, W., Rivera, S. M., Schneider, A., Hagerman, R. J., Faradz, S. M. H., Ethell, I. M., & Nguyen, D. V. (2010) · American Journal on Intellectual and Developmental Disabilities · doi:10.1352/1944-7558-115.5.433 · Cited by 105 · cited 1×
“In a pilot open label study on 50 FXS individuals, minocycline treatment improved cognition, language and behavior [161].”
BackgroundChronic administration of AFQ056/Mavoglurant restores social behaviour in Fmr1 knockout mice
Gantois, I., Pop, A. S., de Esch, C. E. F., Buijsen, R. A. M., Pooters, T., Gomez-Mancilla, B., Gasparini, F., Oostra, B. A., D’Hooge, R., & Willemsen, R. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.10.059 · Cited by 100
Long-lasting effects of minocycline on behavior in young but not adult Fragile X mice.
Dansie, L. E., Phommahaxay, K., Okusanya, A. G., Uwadia, J., Huang, M., Rotschafer, S. E., Razak, K. A., Ethell, D. W., & Ethell, I. M. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.058 · Cited by 95 · cited 1×
“Mmp9 MMP9 :Protein [41, 166] Spine abnormality, anxiety phenotype in elevate plus maze, AGS, hyperactivity, communication [41, 56, 164] Minocycline”
BackgroundEpigenetic analysis reveals a euchromatic configuration in the FMR1 unmethylated full mutations
Tabolacci, E., Moscato, U., Zalfa, F., Bagni, C., Chiurazzi, P., & Neri, G. (2008) · European Journal of Human Genetics · doi:10.1038/ejhg.2008.130 · Cited by 91 · cited 1×
“Nevertheless, the level of FMRP is significantly reduced in FXS samples as compared to the samples from unaffected individuals [12, 14], indicating that the expanded CGG repeats in the 50 UTR may also affect translation efficiency [15].”
BackgroundShang, Y., Wang, H., Mercaldo, V., Li, X., Chen, T., & Zhuo, M. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06314.x · Cited by 72 · cited 2×
“Interestingly, lower LTP in Fmr1 mutants is slightly dampened by the mGluR1/5 antagonist DL-AP-3 but not by the NMDAR antagonist APV [115].”
BackgroundSelf-citation
Cited by
Dendritic Spine Plasticity: Function and Mechanisms
Runge, K., Cardoso, C., & de Chevigny, A. (2020) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2020.00036 · Cited by 231
Li, Y., Abdourahman, A., Tamm, J. A., Pehrson, A. L., Sánchez, C., & Gulinello, M. (2015) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.05.013 · Cited by 79
“The protein coded by Fmr1 (the Fragile X mental retardation protein, FMRP) regulates translation of a variety ofmRNAs (Sethna et al., 2014).”
Persistent astrocyte activation in the fragile X mouse cerebellum
Pacey, L. K. K., Guan, S., Tharmalingam, S., Thomsen, C., & Hampson, D. R. (2015) · Brain and Behavior · doi:10.1002/brb3.400 · Cited by 39
Auditory Dysfunction in Animal Models of Autism Spectrum Disorder
Castro, A. C., & Monteiro, P. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.845155 · Cited by 34
Metadata
- Authors
- Sethna, F., Moon, C., & Wang, H.
- Venue
- Neurochemical Research
- Published
- 2013-12-18
- Volume
- 39
- Issue
- 6
- Pages
- 1016-1031
- ISSN
- 0364-3190 (ISSN-L)
- 1573-6903
- OpenAlex
- W1996046156
- Cited by
- 47
- References
- 80
- FWCI
- 1.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.